Haemonetics' New Alliance Marks Important Milestone in its Nano Program

Haemonetics Corporation (NYSE: HAE), a global blood management solutions company, today announced that it has entered into a reagent development and supply agreement with Quotient Biodiagnostics Group and its wholly owned subsidiary Alba Bioscience Limited.

This arrangement provides Haemonetics with exclusive access to Alba's comprehensive catalogue of approved reagents for use in connection with the commercialization of its Arryx laser based blood typing platform. The arrangement includes future milestone payments in connection with the optimization of reagents for use in the Arryx system.  Access to the reagents for commercialization is provided through a perpetual license.

Brian Concannon, Haemonetics' President and CEO, said, "Blood typing represents a future $1 billion market opportunity for Haemonetics through the ongoing development of our Arryx technology.  I am pleased to report this important milestone in our innovative nano-technology development program targeted at the blood diagnostics market.  We look forward to updating our shareholders on our progress with Arryx at our upcoming investor day scheduled for May 13th."

Paul Cowan, Chairman of Quotient Biodiagnostics, said, "We are pleased to be working with Haemonetics on this exciting new technology platform for the transfusion diagnostics market.  Alba's portfolio of world-leading blood typing reagents will no doubt serve to facilitate and accelerate the development of the Arryx platform for Haemonetics."

Source: http://www.haemonetics.com.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.